Process and methods

5 Production

5.1 Equality and diversity considerations

The QIPP key therapeutics document is developed in accordance with the NICE equality scheme.

5.2 Process and timescales

The QIPP key therapeutics document is not formal NICE guidance and therefore is not subject to the same intensity of process as other NICE products.

Table 1 shows the key steps in the annual update of the QIPP key therapeutics document.

Table 1 Key steps of development of the QIPP key therapeutics document with timelines

Key Step

Timescale

Topic identification, prioritisation and selection

QIPP WRG identify potential key therapeutic topics to be retained, retired or added, to produce draft scope

Early July

QIPP WRG prioritise topics and amend draft list of topics as appropriate

End July/Early August

Draft list of topics published on NICE website for feedback: Partners and NHS organisations feedback commences

Mid Sept

Partners and NHS organisations feedback ends

Mid Oct

QIPP WRG consider feedback, NICE Medicines and Prescribing Centre produce final list of topics to be agreed by NICE Guidance Executive

End Oct

Production

NICE Medicines and Prescribing Centre scope individual topic content

Early Nov

NICE Medicines and Prescribing Centre senior advisers author content

Early Nov

NICE Medicines and Prescribing Centre senior advisers technical check of content

Mid Nov

Check of content by NICE Medicines and Prescribing Centre associate director and programme director

End Nov

Draft document sent to QIPP WRG and QIPP Partners Group

Early Dec

NICE Medicines and Prescribing Centre revise draft as appropriate

Mid December

NICE Medicines and Prescribing Centre senior advisers editorial check of content

Mid December

Final check of content by NICE Medicines and Prescribing Centre associate director and programme director

End December

Editorial check of content by NICE Editorial team

Early January

NICE Publication Executive sign off

Mid January

Publication on NICE website

End January

5.3 Scoping of selected topics for the QIPP key therapeutics document

The NICE Medicines and Prescribing Centre will hold an internal meeting to scope the content for each selected key therapeutic topic (either an existing topic or a new topic) to:

  • Identify and review important, 'high-level', therapeutic evidence for each key therapeutic topic, such as NICE guidance, MHRA recommendations, or NICE Medicines and Prescribing Centre outputs.

  • Identify QIPP prescribing comparators and other relevant prescribing data for each key therapeutic topic.

  • Agree the content for each key therapeutic topic, to ensure current best practice and prescribing issues for each topic are up to date.

  • Agree if any key therapeutic topic requires a literature search. A literature search is only considered if national guidance, advice or policy is not available. For most topics a literature search will not be required.

5.4 Authoring of the QIPP key therapeutics document

NICE Medicines and Prescribing Centre senior advisers draft the content of the QIPP key therapeutics document using a standard template, which includes the following sections:

  • Title and contents page

  • Date and version control information

  • Foreword

  • For each key therapeutic topic

    • Options for local implementation

    • Evidence context

    • Prescribing data.

5.5 Review of the QIPP key therapeutics document

The NICE Medicines and Prescribing Centre sends the draft QIPP key therapeutics document to key NICE teams, including clinical guidelines and technology appraisals, and the Department of Health's QIPP Wider Reference Group (WRG) and QIPP Partners Group for comment. Comments will be invited ONLY for a 2-week period. Feedback will be collated by NICE Medicines and Prescribing Centre staff and draft responses produced for each element of feedback. Any comments received will be considered within the production of the revised draft.

5.6 Quality assurance of the QIPP key therapeutics document

NICE Medicines and Prescribing Centre senior advisers quality assure the document to a checklist. This will involve a detailed check of all content to ensure all sections of the document contain statements and conclusions that are fair and balanced. They must accurately reflect the evidence reviewed and be substantiated by an explicit and appropriate source of evidence. A further check for clarity, grammar, spelling and style is also undertaken. All drafts and any changes to drafts are recorded for audit purposes.

The NICE Medicines and Prescribing Centre, in conjunction with the NICE Editorial team, produce a final draft. Once sign-off is received from the Programme Director of the NICE Medicines and Prescribing Centre, NICE Publication Executive reviews the QIPP key therapeutics document and if appropriate approves the document for publication, ensuring that due process has been followed in its development.

5.7 Publication of the QIPP key therapeutics document

The final QIPP key therapeutics document will be uploaded and made available on the NICE website.